Eledon Pharmaceuticals Inc. Watch

from SC 13G 1 page Agreement

from 8-K 57 pages Eledon Pharmaceuticals, Inc. (A Delaware Corporation) 18,356,173 Shares of Common Stock Pre-Funded Warrants to Purchase Up to 4,931,507 Shares of Common Stock Underwriting Agreement

from S-3 39 pages Open Market Sale Agreement

from 10-K 38 pages Open Market Sale Agreementsm

from S-1/A 45 pages [●] Shares Novus Therapeutics, Inc. Common Stock Underwriting Agreement

from 8-K 45 pages Novus Therapeutics, Inc. Shares of Common Stock (Par Value $0.001 Per Share) Equity Distribution Agreement

from S-1/A 44 pages Tokai Pharmaceuticals, Inc., a Delaware Corporation (The “Company”), Proposes, Subject to the Terms and Conditions Stated Herein, to Issue and Sell an Aggregate of [ ] Shares (The “Firm Shares”) of the Company’s Common Stock, $0.001 Par Value Per Share (The “Common Stock”), to the Several Underwriters (Collectively, the “Underwriters”) Named in Schedule I to This Agreement (This “Agreement”), for Whom Bmo Capital Markets Corp. (“Bmocm”), Stifel, Nicolaus & Company, Incorporated (“Stifel”) and William Blair & Company, L.L.C. Are Acting as Representatives (The “Representatives”). the Company Has Also Agreed to Grant to the Underwriters an Option (The “Option”) to Purchase Up to an Additional [ ] Shares of Common Stock (The “Option Shares”) on the Terms Set Forth in Section 1(b). the Firm Shares and the Option Shares Are Hereinafter Collectively Referred to as the “Shares.” the Company Confirms as Follows Its Agreement With the Representatives and the Several Other Underwriters: 1. Agreement to Sell and Purchase